Cancer cell adaptation to chemotherapy

Federica Di Nicolantonio, Stuart J. Mercer, Louise A. Knight, Francis G. Gabriel, Pauline A. Whitehouse, Sanjay Sharma, Augusta Fernando, Sharon Glaysher, Silvana Di Palma, Penny Johnson, Shaw S. Somers, Simon Toh, Bernie Higgins, Alan Lamont, Tim Gulliford, Jeremy Hurren, Constantinos Yiangou, Ian A. Cree

Research output: Contribution to journalArticle

Abstract

Background: Tumor resistance to chemotherapy may be present at the beginning of treatment, develop during treatment, or become apparent on re-treatment of the patient. The mechanisms involved are usually inferred from experiments with cell lines, as studies in tumor-derived cells are difficult. Studies of human tumors show that cells adapt to chemotherapy, but it has been largely assumed that clonal selection leads to the resistance of recurrent tumors. Methods: Cells derived from 47 tumors of breast, ovarian, esophageal, and colorectal origin and 16 paired esophageal biopsies were exposed to anticancer agents (cisplatin; 5-fluorouracil; epirubicin; doxorubicin; paclitaxel; irinotecan and topotecan) in short-term cell culture (6 days). Real-time quantitative PCR was used to measure up- or down-regulation of 16 different resistance/target genes, and when tissue was available, immunohistochemistry was used to assess the protein levels. Results: In 8/16 paired esophageal biopsies, there was an increase in the expression of multi-drug resistance gene 1 (MDR1) following epirubicin + cisplatin + 5-fluorouracil (ECF) chemotherapy and this was accompanied by increased expression of the MDR-1 encoded protein, P-gp. Following exposure to doxorubicin in vitro, 13/14 breast carcinomas and 9/12 ovarian carcinomas showed >2- fold down-regulation of topoisomerase IIα (TOPOIIα). Exposure to topotecan in vitro, resulted in >4-fold down-regulation of TOPOIIα in 6/7 colorectal tumors and 8/10 ovarian tumors. Conclusion: This study suggests that up-regulation of resistance genes or down-regulation in target genes may occur rapidly in human solid tumors, within days of the start of treatment, and that similar changes are present in pre- and post-chemotherapy biopsy material. The molecular processes used by each tumor appear to be linked to the drug used, but there is also heterogeneity between individual tumors, even those with the same histological type, in the pattern and magnitude of response to the same drugs. Adaptation to chemotherapy may explain why prediction of resistance mechanisms is difficult on the basis of tumor type alone or individual markers, and suggests that more complex predictive methods are required to improve the response rates to chemotherapy.

Original languageEnglish
Article number78
JournalBMC Cancer
Volume5
DOIs
Publication statusPublished - Jul 18 2005

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Genetics

Fingerprint Dive into the research topics of 'Cancer cell adaptation to chemotherapy'. Together they form a unique fingerprint.

  • Cite this

    Di Nicolantonio, F., Mercer, S. J., Knight, L. A., Gabriel, F. G., Whitehouse, P. A., Sharma, S., Fernando, A., Glaysher, S., Di Palma, S., Johnson, P., Somers, S. S., Toh, S., Higgins, B., Lamont, A., Gulliford, T., Hurren, J., Yiangou, C., & Cree, I. A. (2005). Cancer cell adaptation to chemotherapy. BMC Cancer, 5, [78]. https://doi.org/10.1186/1471-2407-5-78